A translational research on miR-224: towards novel diagnostic and therapeutic approach for hepatocellular carcinoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590953
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Yamagata University
• Principal Investigator: SHO Ri 山形大学, 医学(系)研究科(研究院), 助教 (80344787)
• Co-Investigator(Kenkyū-buntansha): WATANABE Hisayoshi 山形大学, 医学部, 講師 (00332536) ; ISHII Rika 山形大学, 医学部, 助教 (60466612) ; ZHANG Xuhong 山形大学, 大学院医学系研究科, 助教 (10292442)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 肝癌 / microRNA / 分子標的治療 / 診断マーカー

Outline of Final Research Achievements

Our previous study has determined that aberrant expression of miR-224 in hepatocellular carcinoma (HCC) was associated with cancer cell invasion. Using mouse xenograft model, we further investigated whether miR-224 could serve as a potential target for HCC therapy. Inoculation of HCC cells transfected with miR-224 inhibitor (antagomiR-224) into subcutaneous of athymic nude mice revealed that inhibition of miR-224 in HCC cells significantly delayed tumor formation as compared to control. Direct intratumoral injection of antagomiR-224 didn’t cause tumor regression, but did show a delay in tumor growth in comparison to mice treated with control substance, suggesting that miR-224 may serve as a potential therapeutic target in HCC.

Free Research Field

肝臓学